article thumbnail

GSK antibody drug reduces COPD attacks in trial

Bio Pharma Dive

New trial results could offer support for an expansion of Nucala’s label after U.S. regulators rejected GSK’s submission in 2018.

Trials 164
article thumbnail

Antibody-drug conjugate for solid tumours enters Phase I trials

Drug Discovery World

The first patient has been dosed in a Phase I clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers. We look forward to evaluating AGX101 in this trial.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Summit, Akeso's antibody triumphs over Keytruda in China lung cancer trial, sending shares skyrocketing

Fierce Pharma

Just one week after Summit Therapeutics and Akeso’s bispecific antibody ivonescimab passed muster with Chinese regulators, the drug has pulled off another feat by staring down the PD-1 king Keytrud | In the phase 3 HARMONi-2 trial, solo ivonescimab delivered a statistically significant and clinically meaningful improvement in progression-free survival (..)

Antibody 113
article thumbnail

US FDA approves Eisai-Biogen’s antibody for Alzheimer’s

Pharmaceutical Technology

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

article thumbnail

Trial to test monoclonal antibody for virus of growing concern

Drug Discovery World

The National Institutes of Health (NIH) is sponsoring a clinical trial to evaluate the safety of an investigational monoclonal antibody to treat enterovirus D68 (EV-D68), which can cause severe respiratory and neurological diseases such as acute flaccid myelitis (AFM). Credit: NIAID and CDC.

article thumbnail

Regeneron antibody cuts risk of COVID-19 death in UK study

Bio Pharma Dive

The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients.

Antibody 327
article thumbnail

Monoclonal antibody CB1 inhibitor for obesity enters Phase II trials

Drug Discovery World

Skye Bioscience has started screening patients for a Phase II clinical trial (CBeyond) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. Assessing psychiatric effects of CB1 inhibition The clinical trial will enrol 120 patients across four treatment groups.